Epigenomics Epigenomics Reports 24 Percent Drop in 2020 Revenues, Seeks Sale After Negative Coverage Decision The firm said that due to a negative coverage decision and capital constraints, it is evaluating options including a sale by a public takeover or an asset deal. CMS Finalizes Blood-Based Colon Cancer Screening NCD with Non-Coverage for Epi ProColon The final decision includes some changes, most notably removing requirements for guideline inclusion, but retains its technical performance benchmarks. Epigenomics Issues €5.5M Convertible Bond The proceeds of the bond are going to support the firm's operations as it awaits a final Medicare coverage decision on its colon cancer test. Epigenomics Posts 30 Percent Rise in Q3 Revenues A negative preliminary decision regarding reimbursement for the company's flagship colon cancer screening test in the US remains an issue for the company. Epigenomics Q2 Revenues Slide 76 Percent on Coronavirus Challenges The firm's US clinical trials came to a standstill in the second quarter, affecting its post-approval study for the Epi proColon colorectal cancer liquid-biopsy test. May 7, 2020 Epigenomics Q1 Revenues Down 28 Percent Apr 29, 2020 Epigenomics Preliminary Q1 Revenues Drop 33 Percent Feb 29, 2020 CMS Seeks Public Input on Epigenomics' National Coverage Request for Colon Cancer Screening Test Nov 19, 2019 Epigenomics Posts 69 Percent Drop in Q3 Revenues Aug 7, 2019 Epigenomics Q2 Revenues Slide 25 Percent May 10, 2019 Guardant Health Announces Plans for Prospective Colorectal Cancer Screening Study Premium May 8, 2019 Epigenomics Q1 Revenues Rise 7 Percent Mar 27, 2019 Epigenomics 2018 Revenues Down 21 Percent Mar 13, 2019 BioChain Threatens Legal Action Against Epigenomics for Contract Termination Mar 6, 2019 Epigenomics Terminates BioChain Licensing Deal; Provides 2019 Revenue Outlook Dec 27, 2018 Epigenomics Pushes New Promotion Efforts for ProColon Test as Other Assays in Pipeline Advance Premium Dec 21, 2018 In Brief This Week: QuantuMDx, Molbio, Seegene, Qiagen, Epigenomics, More Nov 7, 2018 Epigenomics Posts 57 Percent Rise in Q3 Revenues Aug 8, 2018 Epigenomics Posts 88 Percent Increase in Q2 Revenues May 9, 2018 Epigenomics Posts 10 Percent Q1 Revenue Increase Mar 23, 2018 Epigenomics 2017 Revenues Down 55 Percent Dec 19, 2017 Epigenomics Lung Cancer Test Receives CE-IVD Mark Sep 21, 2017 Epigenomics Initiates €5.5M Private Placement Aug 9, 2017 Epigenomics Reports 81 Percent Drop in Q2 Revenues; Takeover Bid Fails Jul 7, 2017 Epigenomics Lowers Revenue Guidance for 2017 Load More Breaking News Roche Receives EUA for PCR-Based, Point-of-Care SARS-CoV-2 Test Decode Study Identifies Proteomic Predictors of All-Cause Mortality In Brief This Week: Natera, Bruker, Bayer, and More New Products Posted to GenomeWeb: Labcorp, Omniseq, Dovetail Genomics, DNA Script, More People in the News: New Appointments at Sema4, Strata Oncology, Bionano Genomics, More Co-Diagnostics Gets CE Mark for Saliva-Based Molecular SARS-CoV-2 Test The Scan Billions for Antivirals The US is putting $3.2 billion toward a program to develop antivirals to treat COVID-19 in its early stages, the Wall Street Journal reports. NFT of the Web Tim Berners-Lee, who developed the World Wide Web, is auctioning its original source code as a non-fungible token, Reuters reports. 23andMe on the Nasdaq 23andMe's shares rose more than 20 percent following its merger with a special purpose acquisition company, as GenomeWeb has reported. Science Papers Present GWAS of Brain Structure, System for Controlled Gene Transfer In Science this week: genome-wide association study ties variants to white matter stricture in the brain, and more.